Supplementary Tables 1, 2, 3, 9A - 9C, 14, 15, 16, 21

Supplementary Tables 1, 2, 3, 9A - 9C, 14, 15, 16, 21Supplementary Table 21 is the source data for figure 5 Supplementary Table legends: Supplementary Table 1. Distribution of samples with varying molecular characterization available for analysis.Supplementary Table 2. Association between genomic context, tumor type, grade with A) 5-hmC MDI and B) 5-mC MDI, determined by linear regression.Supplementary Table 3. Association between tumor purity, grade with A) 5-hmC MDI and B) 5-mC MDI, determined by linear regression.Supplementary Table 9. A) Annotation of gene name and genomic context of 28 dhmCpGs shared across tumor types. B) Proportion of shared dhmCpGs relative to CpG islands. C) Proportion of shared dhmCpGs in different genomic contexts.Supplementary Table 14. The number of differentially expressed genes with differentially hydroxymethylated CpGs identified by bulk tissue epigenome-wide association study. Categorized by the direction of gene expression change and the genomic context of the differentially hydroxymethylated CpGs for each tumor type.Supplementary Table 15. The number of nuclei from single nuclei RNA-seq that were included in the CellDMC analysis.Supplementary Table 16. The number of differentially hydroxymethylated CpGs per tumor type identified by CellDMC. Categorized by the change in the level of hydroxymethylation and cell type of association.Supplementary Table 21. Cell type-driven dhmCpGs and dmCpGs enrichment at genomic contexts.

补充表1、2、3、9A~9C、14、15、16、21。其中补充表21为图5的源数据。补充表图例说明如下：
补充表1：可供分析的不同分子特征类型样本的分布情况。
补充表2：通过线性回归分析得到的基因组区域背景、肿瘤类型、肿瘤分级与A) 5-羟甲基胞嘧啶甲基化差异指数（5-hmC MDI）、B) 5-甲基胞嘧啶甲基化差异指数（5-mC MDI）之间的关联关系。
补充表3：通过线性回归分析得到的肿瘤纯度、肿瘤分级与A) 5-羟甲基胞嘧啶甲基化差异指数（5-hmC MDI）、B) 5-甲基胞嘧啶甲基化差异指数（5-mC MDI）之间的关联关系。
补充表9：A) 跨肿瘤类型共有的28个差异羟甲基化CpG位点（dhmCpGs）的基因名称及基因组区域背景注释；B) 共有的差异羟甲基化CpG位点在CpG岛中的占比；C) 共有的差异羟甲基化CpG位点在不同基因组区域背景中的占比。
补充表14：通过批量组织表观基因组全关联研究鉴定得到的、与差异羟甲基化CpG位点相关的差异表达基因数量，按各肿瘤类型的基因表达变化方向及差异羟甲基化CpG位点的基因组区域背景进行分类。
补充表15：纳入CellDMC分析的单细胞核RNA测序所得的细胞核数量。
补充表16：通过CellDMC鉴定得到的各肿瘤类型的差异羟甲基化CpG位点数量，按羟甲基化水平变化方向及关联细胞类型进行分类。
补充表21：细胞类型驱动的差异羟甲基化CpG位点（dhmCpGs）与差异甲基化CpG位点（dmCpGs）在基因组区域背景中的富集情况。